Moncef Slaoui, the former head of GlaxoSmithKline vaccines division, listens as U.S. President Donald Trump delivers remarks about coronavirus vaccine development in the Rose Garden of the White House on May 15, 2020 in Washington, D.C. (Photo: Drew Angerer/Getty Images)
'This Is My Retirement': Trump's Covid-19 Vaccine Czar Refuses to Sell Stock Holdings of Major Drug Company
"If he retains stock in companies that are investing in the development of a vaccine," said government watchdog CREW, "we can't be confident of the integrity of any process in which he is involved."
The chief adviser overseeing President Donald Trump's task force charged with spearheading the U.S. government's Covid-19 vaccine and treatment effort has refused to divest his shares in pharmaceutical company GlaxoSmithKline, where he previously worked.
As the New York Times reported Wednesday, Dr. Moncef Slaoui, who was appointed to lead Operation Warp Speed last week, holds nearly $10 million in stock at the company where he led the vaccine division until his retirement in 2017. Slaoui still owns an unknown number of shares at GSK, where he held about 240,000 shares and share equivalents when he left the company.
GSK is one of several pharmaceutical companies researching potential vaccines for the coronavirus.
Slaoui reportedly told the Trump administration that he would not sell his GSK shares.
"I have worked for 29 years for GSK," Slaoui told the Times. "I have never sold a single share of any company in my life. This is my retirement. What I said regarding the GSK shares, I said I cannot take the job if I have to sell them."
Critics charge Slaoui's interest in GSK represents just one of his conflicts as he leads a task force which will decide which vaccine candidates should receive financial backing.
The doctor has retained his partnership in the venture capital firm Medicxi, which has investments in a number of companies researching vaccines and treatments.
Under Slaoui's arrangement with the Trump administration, he is working on Operation Warp Speed as a contractor rather than a federal employee, shielding him from conflict of interest laws and financial disclosure rules--a deal the government watchdog Citizens of Responsibility and Ethics in Washington (CREW) called "absurd."
"It allows for no public scrutiny of his conflicts of interest," chief ethics counsel Virginia Canter told the Times. "If he retains stock in companies that are investing in the development of a vaccine, and he's involved in overseeing this process to select the safest vaccine to combat Covid-19, regardless of how wonderful a person he is, we can't be confident of the integrity of any process in which he is involved."
Last week, Sen. Elizabeth Warren (D-Mass.) called on Slaoui to "immediately divest" his financial interests in Moderna, another pharmaceutical company researching a vaccine. When Slaoui accepted his new position, he still held stock options in the company, amounting to what Warren called "a huge conflict of interest."
Slaoui did not sell those shares until this Tuesday, a day after Moderna's stock skyrocketed when the company released partial data from an early vaccine trial, which showed eight out of 45 test subjects had developed Covid-19 immunity.
Slaoui's stock options increased by more than $2 million after the announcement; the Trump administration said he was planning to donate the increased value to cancer research.
Despite Moderna's rising stock during its vaccine trial demonstrating how Slaoui's involvement in the task force creates conflicts for the doctor, the White House told the Times it had "reviewed Dr. Slaoui's affiliations with several companies and concluded in several instances that there were no conflicts because his advisory roles were unrelated to coronavirus research or treatments."
On Thursday, former Office of Government Ethics director Walter Shaub tweeted that the arrangement allowing Slaoui to work as a contractor while overseeing government employees working on Operation Warp Speed is a "sham."
Slaoui's position on the task force "would make him a special government employee subject to the criminal conflict of interest law," wrote Shaub. "Congress needs to investigate!"
We are at a crossroads
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. Our Fall Campaign is underway, and we need your help. To power our newsroom through the rest of the year, we need to raise $125,000 by midnight on October 31. So if you share our vision, please contribute whatever you can to sustain our work. |
The chief adviser overseeing President Donald Trump's task force charged with spearheading the U.S. government's Covid-19 vaccine and treatment effort has refused to divest his shares in pharmaceutical company GlaxoSmithKline, where he previously worked.
As the New York Times reported Wednesday, Dr. Moncef Slaoui, who was appointed to lead Operation Warp Speed last week, holds nearly $10 million in stock at the company where he led the vaccine division until his retirement in 2017. Slaoui still owns an unknown number of shares at GSK, where he held about 240,000 shares and share equivalents when he left the company.
GSK is one of several pharmaceutical companies researching potential vaccines for the coronavirus.
Slaoui reportedly told the Trump administration that he would not sell his GSK shares.
"I have worked for 29 years for GSK," Slaoui told the Times. "I have never sold a single share of any company in my life. This is my retirement. What I said regarding the GSK shares, I said I cannot take the job if I have to sell them."
Critics charge Slaoui's interest in GSK represents just one of his conflicts as he leads a task force which will decide which vaccine candidates should receive financial backing.
The doctor has retained his partnership in the venture capital firm Medicxi, which has investments in a number of companies researching vaccines and treatments.
Under Slaoui's arrangement with the Trump administration, he is working on Operation Warp Speed as a contractor rather than a federal employee, shielding him from conflict of interest laws and financial disclosure rules--a deal the government watchdog Citizens of Responsibility and Ethics in Washington (CREW) called "absurd."
"It allows for no public scrutiny of his conflicts of interest," chief ethics counsel Virginia Canter told the Times. "If he retains stock in companies that are investing in the development of a vaccine, and he's involved in overseeing this process to select the safest vaccine to combat Covid-19, regardless of how wonderful a person he is, we can't be confident of the integrity of any process in which he is involved."
Last week, Sen. Elizabeth Warren (D-Mass.) called on Slaoui to "immediately divest" his financial interests in Moderna, another pharmaceutical company researching a vaccine. When Slaoui accepted his new position, he still held stock options in the company, amounting to what Warren called "a huge conflict of interest."
Slaoui did not sell those shares until this Tuesday, a day after Moderna's stock skyrocketed when the company released partial data from an early vaccine trial, which showed eight out of 45 test subjects had developed Covid-19 immunity.
Slaoui's stock options increased by more than $2 million after the announcement; the Trump administration said he was planning to donate the increased value to cancer research.
Despite Moderna's rising stock during its vaccine trial demonstrating how Slaoui's involvement in the task force creates conflicts for the doctor, the White House told the Times it had "reviewed Dr. Slaoui's affiliations with several companies and concluded in several instances that there were no conflicts because his advisory roles were unrelated to coronavirus research or treatments."
On Thursday, former Office of Government Ethics director Walter Shaub tweeted that the arrangement allowing Slaoui to work as a contractor while overseeing government employees working on Operation Warp Speed is a "sham."
Slaoui's position on the task force "would make him a special government employee subject to the criminal conflict of interest law," wrote Shaub. "Congress needs to investigate!"
The chief adviser overseeing President Donald Trump's task force charged with spearheading the U.S. government's Covid-19 vaccine and treatment effort has refused to divest his shares in pharmaceutical company GlaxoSmithKline, where he previously worked.
As the New York Times reported Wednesday, Dr. Moncef Slaoui, who was appointed to lead Operation Warp Speed last week, holds nearly $10 million in stock at the company where he led the vaccine division until his retirement in 2017. Slaoui still owns an unknown number of shares at GSK, where he held about 240,000 shares and share equivalents when he left the company.
GSK is one of several pharmaceutical companies researching potential vaccines for the coronavirus.
Slaoui reportedly told the Trump administration that he would not sell his GSK shares.
"I have worked for 29 years for GSK," Slaoui told the Times. "I have never sold a single share of any company in my life. This is my retirement. What I said regarding the GSK shares, I said I cannot take the job if I have to sell them."
Critics charge Slaoui's interest in GSK represents just one of his conflicts as he leads a task force which will decide which vaccine candidates should receive financial backing.
The doctor has retained his partnership in the venture capital firm Medicxi, which has investments in a number of companies researching vaccines and treatments.
Under Slaoui's arrangement with the Trump administration, he is working on Operation Warp Speed as a contractor rather than a federal employee, shielding him from conflict of interest laws and financial disclosure rules--a deal the government watchdog Citizens of Responsibility and Ethics in Washington (CREW) called "absurd."
"It allows for no public scrutiny of his conflicts of interest," chief ethics counsel Virginia Canter told the Times. "If he retains stock in companies that are investing in the development of a vaccine, and he's involved in overseeing this process to select the safest vaccine to combat Covid-19, regardless of how wonderful a person he is, we can't be confident of the integrity of any process in which he is involved."
Last week, Sen. Elizabeth Warren (D-Mass.) called on Slaoui to "immediately divest" his financial interests in Moderna, another pharmaceutical company researching a vaccine. When Slaoui accepted his new position, he still held stock options in the company, amounting to what Warren called "a huge conflict of interest."
Slaoui did not sell those shares until this Tuesday, a day after Moderna's stock skyrocketed when the company released partial data from an early vaccine trial, which showed eight out of 45 test subjects had developed Covid-19 immunity.
Slaoui's stock options increased by more than $2 million after the announcement; the Trump administration said he was planning to donate the increased value to cancer research.
Despite Moderna's rising stock during its vaccine trial demonstrating how Slaoui's involvement in the task force creates conflicts for the doctor, the White House told the Times it had "reviewed Dr. Slaoui's affiliations with several companies and concluded in several instances that there were no conflicts because his advisory roles were unrelated to coronavirus research or treatments."
On Thursday, former Office of Government Ethics director Walter Shaub tweeted that the arrangement allowing Slaoui to work as a contractor while overseeing government employees working on Operation Warp Speed is a "sham."
Slaoui's position on the task force "would make him a special government employee subject to the criminal conflict of interest law," wrote Shaub. "Congress needs to investigate!"